epcoritamab,rituximab
abbvie,genmab,biogen,roche
['lymsm', 'dlbcl', 'epcoritamab']
frontline subcutaneous epcoritamab plus r-chop elicits orr of 100% in high-risk dlbcl #eha22 #lymsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.